Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METADUR: Azacitidine + Durvalumab in Advanced Solid Tumors
NCT02811497Phase 2Completed
- Sponsor
- University Health Network
- Start
- Sep 2016
- Primary completion
- Nov 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and durvalumab in colorectal carcinoma (CRC), ovarian cancer and breast cancer, sponsored by University Health Network. Primary endpoint: Overall Response Rate at 4 weeks. Started Sep 2016; status: completed.
02
Drugs
azacitidinedurvalumab
03
Conditions
colorectal carcinoma (CRC)ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT02811497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811497.